What Are the Challenges in Targeting the G2 Phase for Cancer Therapy?
While targeting the G2 phase presents promising therapeutic avenues, there are challenges. Cancer cells are heterogeneous, and not all cells within a tumor may rely on the same mechanisms for G2 phase progression. Moreover, normal cells also depend on the G2 phase for growth and repair, raising the risk of collateral damage and toxicity when targeting this phase.
